Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 3 Comparison of clinicopathological features by subtype

From: Clinical verification of the relationship between smoking and the immune microenvironment of breast cancer

Parameters Intrinsic subtype p value
HER2-enriched breast cancer (n = 62) Triple-negative breast cancer (n = 87)
Age (years old)
 ≤ 56 26 (41.9%) 49 (56.3%) 0.085
 > 56 36 (58.1%) 38 (43.7%)
Tumour size (mm)
 ≤ 27.6 30 (48.4%) 45 (51.7%) 0.690
 > 27.6 32 (51.6%) 42 (48.3%)
Skin infiltration
 Negative 54 (87.1%) 80 (92.0%) 0.335
 Positive 8 (12.9%) 7 (8.0%)
Lymph node status
 Negative 25 (40.3%) 26 (29.9%) 0.188
 Positive 37 (59.7%) 61 (70.1%)
Ki67
 Negative 14 (22.6%) 9 (10.3%) 0.042
 Positive 48 (77.4%) 78 (89.7%)
ORR
 Non-responders 1 (1.6%) 10 (11.5%) 0.023
 Responders 61 (98.4%) 77 (88.5%)
pCR
 Negative 26 (41.9%) 49 (56.3%) 0.085
 Positive 36 (58.1%) 38 (43.7%)
Recurrence
 Negative 55 (88.7%) 68 (78.2%) 0.096
 Positive 7 (11.3%) 19 (21.8%)
TILs
 Low 20 (32.3%) 38 (43.7%) 0.206
 High 42 (67.7%) 49 (56.3%)
Pack-years
 Low 40 (64.5%) 66 (75.9%) 0.134
 High 22 (35.5%) 21 (24.1%)
  1. HER human epidermal growth factor receptor, ORR objective response rate, pCR pathological complete response, TILs tumour-infiltrating lymphocytes